98%
921
2 minutes
20
Background: When transcatheter aortic valve-in-surgical aortic valve (TAV-in-SAV) is considered as a secondary interventional option, it is desirable to estimate the risk of coronary obstruction during future TAV-in-SAV before the initial surgical aortic valve replacement (SAVR), for which knowledge of the anatomic changes after SAVR is essential. We investigated the changes in the aortic root and evaluated the differences in changes between valve types.
Methods: Pre- and post-SAVR computed tomography scans of 124 patients with aortic stenosis who underwent SAVR with various bioprosthetic valves were analyzed retrospectively. Postoperative aortic root changes and parameters related to future TAV-in-SAV were compared between the sutured valve group and rapid-deployment/sutureless valve group.
Results: After SAVR, the coronary height in the sutured valve group and rapid-deployment/sutureless valve group was shortened by a median of 4.6 to 5.3 mm and 0.5 to 2.2 mm, respectively, and the sinus of Valsalva (SOV) diameter was reduced by a median of 1.6 to 2.7 mm and 0.1 to 1.3 mm, respectively. A significantly higher proportion of patients in the rapid deployment/sutureless valve group had a coronary orifice (especially in the right coronary artery) above the risk plane. The valve-to-coronary distance and valve-to-aorta distance (VTA) were adequate in most patients. The only difference between the groups was in the left VTA.
Conclusions: Decreases in coronary height and SOV diameter were observed after SAVR, especially in the sutured valve group. The aortic root structure was better preserved in the rapid-deployment/sutureless valve group. This may be advantageous for future TAV-in-SAV. These results are important for considering the feasibility of future TAV-in-SAV.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11519014 | PMC |
http://dx.doi.org/10.1016/j.xjtc.2024.07.014 | DOI Listing |
Clin Res Cardiol
September 2025
AGEL Hospital Trinec-Podlesi, Konska 453, Trinec, 739 61, Czech Republic.
Background: Pulmonary hypertension (PH) often coexists in patients undergoing transcatheter edge-to-edge mitral valve repair procedure (M-TEER). Its pre-procedural severity is considered a negative prognostic marker. Whether the post-procedural PH resulting from M-TEER can also serve as a long-term prognostic marker is unknown.
View Article and Find Full Text PDFJTCVS Open
August 2025
Division of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Objective: To compare the clinical outcomes of double-valve replacement (DVR) using bovine pericardial and porcine bioprostheses, using a nationwide administrative claims database.
Methods: Adult patients (age ≥40 years) who underwent bioprosthetic DVR between 2003 and 2018 were identified from the Korean National Health Insurance Service database. The outcomes of interest were all-cause mortality, cardiac mortality, and valve-related events, including the incidences of reoperation, endocarditis, systemic thromboembolism, and major bleeding.
JTCVS Open
August 2025
Division of Cardiovascular Surgery, Children's National Heart Institute, Children's National Hospital, Washington, DC.
Objectives: We sought to review the outcomes of patients with Ebstein anomaly (EA) after the Fontan operation.
Methods: Patients with EA were identified from a large binational registry about the Fontan operation. Data were collected from hospital records, registry data, and clinical correspondence.
JTCVS Open
August 2025
Division of Cardiac Surgery, IRCCS Azienda Ospedaliera-Universitaria di Bologna, Bologna, Italy.
Objective: To compare early and long-term clinical outcomes of bioprosthetic versus mechanical (On-X) mitral valve replacement (MVR) in patients aged 65 years and older.
Methods: This single-center retrospective study included consecutive patients equal to or older than 65 years underwent isolated MVR from 2005 to 2023. A propensity score-matched analysis was performed to compare early- and long-term clinical outcomes between patients with bioprostheses and mechanical On-X valve.
JTCVS Open
August 2025
Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn.
Objectives: To describe the clinical presentation of patients with gonadal neuroendocrine tumors and carcinoid heart disease (CaHD) and to evaluate long-term outcomes following valvular surgery.
Methods: Retrospective review of patients with primary gonadal neuroendocrine tumor who were surgically treated for CaHD at our institution between 1990 and 2021.
Results: Eight patients (median age, 70 years) were included in the study, 7 with ovarian tumors and 1 with testicular tumor.